Your browser is no longer supported. Please, upgrade your browser.
Quidel Corporation
Index- P/E5.35 EPS (ttm)21.75 Insider Own1.50% Shs Outstand42.22M Perf Week7.21%
Market Cap4.44B Forward P/E10.37 EPS next Y11.22 Insider Trans-6.08% Shs Float37.09M Perf Month-5.53%
Income948.10M PEG0.74 EPS next Q4.68 Inst Own87.90% Short Float10.25% Perf Quarter-50.02%
Sales1.86B P/S2.39 EPS this Y971.80% Inst Trans7.81% Short Ratio3.94 Perf Half Y-58.70%
Book/sh31.57 P/B3.69 EPS next Y-46.09% ROA29.30% Target Price185.25 Perf Year-26.61%
Cash/sh12.83 P/C9.07 EPS next 5Y7.20% ROE43.60% 52W Range104.40 - 306.72 Perf YTD-35.21%
Dividend- P/FCF22.93 EPS past 5Y154.30% ROI61.30% 52W High-62.05% Beta0.00
Dividend %- Quick Ratio3.10 Sales past 5Y53.30% Gross Margin82.50% 52W Low11.48% ATR7.02
Employees1370 Current Ratio3.40 Sales Q/Q431.70% Oper. Margin25.10% RSI (14)45.77 Volatility7.58% 5.82%
OptionableYes Debt/Eq0.00 EPS Q/Q1435.10% Profit Margin19.90% Rel Volume0.95 Prev Close120.93
ShortableYes LT Debt/Eq0.00 EarningsMay 06 AMC Payout0.00% Avg Volume965.22K Price116.39
Recom2.50 SMA20-1.34% SMA50-10.69% SMA200-40.69% Volume918,636 Change-3.75%
Jan-22-21Upgrade Raymond James Mkt Perform → Outperform $250
May-12-20Downgrade JP Morgan Neutral → Underweight $120 → $158
Mar-26-20Downgrade Barclays Overweight → Equal Weight $90
Oct-23-18Resumed Raymond James Strong Buy $80
Mar-08-18Upgrade Raymond James Outperform → Strong Buy
Jan-22-18Reiterated Barclays Overweight $50 → $60
Jan-04-18Upgrade CL King Neutral → Buy
Sep-19-17Upgrade Piper Jaffray Neutral → Overweight
Jul-18-17Upgrade William Blair Mkt Perform → Outperform
Jul-18-17Upgrade Canaccord Genuity Hold → Buy $25 → $42
Apr-25-17Reiterated Canaccord Genuity Hold $24 → $24.50
Feb-17-17Initiated CL King Neutral
Dec-16-16Downgrade Piper Jaffray Overweight → Neutral
Jun-13-16Upgrade Raymond James Mkt Perform → Outperform
Feb-18-16Reiterated Barclays Overweight $28 → $22
Feb-09-16Downgrade Canaccord Genuity Buy → Hold $22 → $18
Jan-08-16Reiterated Canaccord Genuity Buy $25 → $22
Dec-14-15Downgrade Raymond James Outperform → Mkt Perform
Sep-02-15Initiated Barclays Overweight $28
Jul-31-13Reiterated Canaccord Genuity Buy $30 → $35
May-07-21 01:58PM  
May-06-21 08:55PM  
May-05-21 08:30PM  
May-04-21 06:00PM  
May-01-21 10:17AM  
Apr-30-21 09:55AM  
Apr-29-21 12:34PM  
Apr-28-21 12:16PM  
Apr-27-21 10:08AM  
Apr-26-21 07:00PM  
Apr-24-21 05:49AM  
Apr-23-21 08:22AM  
Apr-22-21 04:49PM  
Apr-21-21 05:45PM  
Apr-14-21 05:45PM  
Apr-13-21 08:00AM  
Apr-08-21 05:50PM  
Apr-07-21 10:15PM  
Apr-05-21 08:00AM  
Apr-01-21 08:02PM  
Mar-31-21 11:30PM  
Mar-30-21 06:40AM  
Mar-29-21 10:04AM  
Mar-26-21 05:45PM  
Mar-22-21 11:11AM  
Mar-20-21 06:45AM  
Mar-18-21 06:00PM  
Mar-16-21 05:50PM  
Mar-15-21 12:44PM  
Mar-13-21 02:27AM  
Mar-12-21 03:33AM  
Mar-10-21 04:06PM  
Mar-08-21 09:51AM  
Mar-01-21 11:51AM  
Feb-22-21 05:00PM  
Feb-20-21 11:05AM  
Feb-19-21 02:45PM  
Feb-18-21 04:22PM  
Feb-12-21 11:16AM  
Feb-10-21 11:30AM  
Feb-09-21 05:45PM  
Feb-08-21 04:32PM  
Feb-04-21 05:05PM  
Feb-03-21 05:45PM  
Feb-01-21 04:41PM  
Jan-28-21 04:10PM  
Jan-27-21 05:45PM  
Jan-26-21 04:42AM  
Jan-25-21 12:05PM  
Jan-22-21 09:38AM  
Jan-20-21 06:18AM  
Jan-19-21 05:11PM  
Jan-18-21 10:08AM  
Jan-17-21 04:18PM  
Jan-14-21 05:45PM  
Jan-13-21 10:18AM  
Jan-12-21 09:09AM  
Jan-08-21 10:16AM  
Jan-07-21 02:15PM  
Quidel Corporation develops, manufactures, and markets diagnostic testing solutions for applications in infectious diseases, cardiology, thyroid, women's and general health, eye health, gastrointestinal diseases, and toxicology worldwide. It offers Sofia and Sofia 2 fluorescent immunoassay systems; QuickVue, a lateral flow immunoassay products; and InflammaDry and AdenoPlus, a POC products to detect infectious and inflammatory diseases and conditions of the eye. The company also provides Triage MeterPro, a portable testing platform that enables physicians to promote enhanced health outcomes, as well as the detection of certain drugs of abuse; Triage BNP test for use on Beckman Coulter lab analyzers; and Triage TOX drug screen, which provides results for the determination of the presence of drug and/or the major metabolites in urine. In addition, it offers traditional cell lines, specimen collection devices, media, and controls for use in laboratories that culture and test for various human viruses, including respiratory and herpes family viruses; and cell-based products comprising tubes, shell vials, and multi-well plates. Further, the company provides biomarkers, which include clinical and research products for the assessment of osteoporosis and the evaluation of bone resorption/formation; and enzyme linked immunosorbent assays and reagents for the detection of activation products. Additionally, it offers Lyra molecular real-time polymerase chain reaction assays; Solana, an amplification and detection system; and Virena, a wireless cellular data management and surveillance system The company markets its products through distributors and direct sales force for use in physician offices, hospitals, clinical laboratories, reference laboratories, universities, retail and urgent care clinics, pharmacies, and wellness screening centers. Quidel Corporation was incorporated in 1979 and is headquartered in San Diego, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Option Exercise23.4180318,7986,127May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMay 03Sale105.7480384,9095,324May 04 07:45 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Option Exercise16.604,60176,39012,506Mar 19 07:55 PM
Ferenczy William J.SVP, Cardio/Metabolic UnitMar 17Sale136.067,4001,006,8375,106Mar 19 07:55 PM
Kroll WernerSVP, R&DFeb 24Sale173.715,283917,7348,119Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 23Sale166.304,835804,05813,402Feb 24 07:53 PM
Kroll WernerSVP, R&DFeb 22Option Exercise43.5412,784556,67431,021Feb 24 07:53 PM
BRYANT DOUGLAS CPresident & CEOFeb 22Buy165.305,000826,500495,807Feb 22 07:40 PM
Kroll WernerSVP, R&DFeb 22Sale164.1112,7842,097,95518,237Feb 24 07:53 PM
POLAN MARY LAKE PH DDirectorDec 01Sale192.2511,0002,114,79724,329Dec 03 07:32 PM
POLAN MARY LAKE PH DDirectorNov 06Sale284.173,000852,50535,329Nov 06 07:19 PM
SLACIK CHARLES PDirectorNov 05Option Exercise20.824,00983,46715,224Nov 06 07:16 PM
SLACIK CHARLES PDirectorNov 05Sale282.464,0091,132,38811,215Nov 06 07:16 PM
POLAN MARY LAKE PH DDirectorOct 23Option Exercise21.6327,188588,14238,329Oct 27 07:37 PM
POLAN MARY LAKE PH DDirectorOct 12Sale275.8311,7433,239,01511,141Oct 14 07:26 PM
Strobeck MatthewDirectorSep 03Buy155.6340062,25438,145Sep 04 07:09 PM
Strobeck MatthewDirectorSep 02Buy166.657,3001,216,51137,745Sep 04 07:09 PM
BRYANT DOUGLAS CPresident & CEOAug 31Buy174.995,000874,965455,823Sep 01 06:05 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Option Exercise34.142,58288,1439,216Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 20Sale250.002,582645,5006,634Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Option Exercise35.875,610201,21512,244Aug 24 12:03 PM
Abney Michael Donald Jr.SVP - DistributionAug 19Sale250.005,6101,402,5006,634Aug 24 12:03 PM
BRYANT DOUGLAS CPresident & CEOAug 11Buy234.125,0001,170,600450,823Aug 11 08:38 PM
BUECHLER KENNETH FDirectorAug 03Option Exercise14.437,800112,55467,624Aug 05 08:26 PM
STEWARD RANDALL JChief Financial OfficerAug 03Option Exercise18.4621,166390,65724,014Aug 05 08:33 PM
Michael Edward L.DirectorAug 03Buy288.123,5001,008,4046,434Aug 05 08:32 PM
Kroll WernerSVP, R&DAug 03Sale287.482,072595,6504,599Aug 05 08:28 PM
BUECHLER KENNETH FDirectorAug 03Sale289.227,8002,255,94659,824Aug 05 08:26 PM
STEWARD RANDALL JChief Financial OfficerAug 03Sale286.3121,1666,060,1262,848Aug 05 08:33 PM
BRYANT DOUGLAS CPresident & CEOJun 11Buy160.335,000801,670445,823Jun 12 05:53 PM
Kroll WernerSVP, R&DMay 27Option Exercise0.004,37608,975May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Option Exercise20.4668,1521,394,42272,751May 27 07:54 PM
Kroll WernerSVP, R&DMay 22Sale174.4468,15211,888,1494,599May 27 07:54 PM
Bujarski Robert JosephSVP, NA Comm Ops & Gen CounselMay 20Sale189.4120,0003,788,28213,383May 22 07:59 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Option Exercise17.9515,970286,67515,432May 20 08:02 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Option Exercise31.8816,332520,69927,171May 20 08:07 PM
Abney Michael Donald Jr.SVP - DistributionMay 18Sale198.4615,9703,169,3876,634May 20 08:02 PM
STEWARD RANDALL JChief Financial OfficerMay 18Sale185.3520,0003,707,0402,848May 20 08:11 PM
BORKAR RATAN SSVP, Intl Comm OperationsMay 18Sale192.8228,3125,459,113524May 20 08:07 PM
SLACIK CHARLES PDirectorMay 15Option Exercise0.00549011,352May 18 08:16 PM
BUECHLER KENNETH FDirectorMay 15Option Exercise0.001,842059,824May 18 08:06 PM
WIDDER KENNETH JDirectorMay 14Option Exercise0.002,100014,416May 18 08:21 PM
Strobeck MatthewDirectorMay 14Option Exercise0.002,10007,399May 18 08:19 PM
SLACIK CHARLES PDirectorMay 14Option Exercise0.002,100010,803May 18 08:16 PM
SCHULER JACK WDirectorMay 14Option Exercise0.002,10003,103,249May 18 08:14 PM
POLAN MARY LAKE PH DDirectorMay 14Option Exercise0.002,100022,884May 18 08:12 PM
ORDONEZ KATHYDirectorMay 14Option Exercise0.001,85601,856May 18 08:10 PM
Michael Edward L.DirectorMay 14Option Exercise0.002,10002,934May 18 08:08 PM
BUECHLER KENNETH FDirectorMay 14Option Exercise0.002,100057,982May 18 08:06 PM